Citations Appearing in 1998

  1. Auclair, B.G. Sirois, A.H. Ngoc and M.P. Ducharme. Novel pharmacokinetic modeling of transdermal nitroglycerin. Pharmaceutical Research 15(4):614-619, 1998.
  2. Bachur, H.R., L. Lun, P.M. Sun, C.M. Trubey, E.E. Elliott, M.J Egorin, L. Malkas and R. Hickey. Anthracycline antibiotic blockade of SV40 T-antigen helicase action. Biochemical Pharmcokinetics 55:1025-1034, 1998.
  3. Ballow, C.H., G.W. Amsden, V.S. Highet and A. Forrest. Pharmacokinetics of oral Azithromycin in serum, urine, polymorphonuclear leukocytes and inflammatory vs noninflammatory skin blisters in healthy-volunteers. Clinical Drug Investigation 15:159- 167, 1998.
  4. Bauer, K.S., E.C. Kohn, R.M. Lush, S.M. Steinberg, P. Davis, D. Kohler, E. Reed and W.D. Figg. Pharmacokinetics and relative bioavailability of carboxyamido-triazole with respect to food and time of administration: Use of a single model for simultaneous determination of changing parameters. Journal of Pharmacokinetics and Biopharmaceutics 26(6):673-687, 1998.
  5. Berg, S.L., D.J. Murry, C.L. McCully, K. Godwin and F.M. Balis. Pharmacokinetics of 0-6-benzylguanine and its active metabolite B-0X0-0-6-benxylguanine in plasma and cerebrospinal-fluid after intrathecal administration of 0-6-benzylguanine in nonhuman primate. Clinical Cancer Research 4:2891-2894, 1998.
  6. Boucher, B.A., S.R. King, H.L. Wandschneider, W.L. Hickerson, S.D. Hanes, V.L. Herring, T.W. Canada and M.M Hess. Fluconazole pharmacokinetics in burn patients. Antimicrobial Agents and Chemotherapy 42:930-933, 1998.
  7. Bruno, R. D. Hille, A. Riva, N. Vivier, W.W.T.B. Huinnink, A.T. Vanoosterom, S.B. Kaye, J. Verweij, F.V. Fossella, V. Valero, J.R. Rigas, A.D. Seidman, B. Chevallier, P. Fumoleau, H.A. Burris, P.M. Ravclin and L.B. Sheiner. Population pharmacokinetics/ pharmacodynamics of Docetaxel in phase-II studies in patients with cancer. Journal of Clinical Oncology 16:187-196, 1998.
  8. Ching, M.I., B.H. Sung, A. Forrest, M.F. Wilson and J.L Izzo. Vasoreactivity in premenopausal and postmenopausal women – evaluation by pharmacodynamic modeling. Journal of Clinical Pharmacology 38:151-159, 1998.
  9. Chou, C.H., L. Aarons and M. Rowland. Optimal experimental design for precise estimation of the parameters of the axial dispersion model of hepatic elimination. Journal of Pharmacokinetics and Biopharmaceutics 26:595-615, 1998.
  10. Cobelli, C. and A. Caumo. Using what is accessible to measure that which is notnecessity of model of system and review. Metabolism 47:1009-1035, 1998.
  11. Conley, B.A., T.S. Ramsland, D.L. Sentz, S.L. Wu, D.M. Rosen, M. Wollman and J.L. Eiseman. Antitumor activity, distribution, and metabolism of 13-cis-retinoic acid as a single agent or in combination with Tamoxifen in established human MCF-7 xenografts in mice. Cancer Chemotherapy and Pharmacology 43:183-197, 1998.
  12. Drusano, G.L., D.Z. D’Argenio, W. Symonds, P.A. Bilello, J. McDowell, B. Sadler, A. Bye and J.A. Bilello. Nucleoside analog 1592U89 and human immunodeficiency virus protease inhibitor 141W94 are synergistic in vitro. Antimicrobial Agents and Chemotherapy 42(9):2153-2159, 1998.
  13. Drusano, G.L. and D.S. Stein. Mathematical-modeling of the interrelationship of CD4 lymphocyte count and viral load changes induced by the protease inhibitor Indinavir. Antimicrobial Agents and Chemotherapy 42:358-361, 1998.
  14. Ducharme, M.P., L. Verret, D. Brouillette and G. Sirois. Ability of a first-pass pharmacokinetic model to characterize Cyclosporine blood-concentrations after administrations of sandimmune or neoral formulations. Therapeutic Drug Monitoring 20:165-171, 1998.
  15. Dutta, S. and W.F. Ebling. Formulation-dependent pharmacokinetics and pharmacodynamics of Propofol in rats. Journal of Pharmacy and Pharmacology 50:37-42, 1998.
  16. Eckhardt, S.G., S.D. Baker, J.R. Eckardt, T.G. Burke, D.L. Warner, J.G. Kuhn, G. Rodriguez, S. Fields, A.Thurman, L. Smith, M.L. Rothenberg, L. White, P. Wissel, R. Kunka, S. Depee, D. Littlefield, H.A. Burris, D.D. Vonhoff and E.K. Rowinsky. Phase-I and pharmacokinetic study of Gi147211, a water-soluble Camptothecin analog, administered for 5 consecutive days every 3 weeks. Clinical Cancer Research 4:595-604, 1998.
  17. Egorin, M.J. Overview of recent topics in clinical pharmacology of anticancer agents. Cancer Chemotherapy and Pharmacology 42:S22-S30, 1998.
  18. Egorin, M.J., D.M. Rosen, R. Sridhara, L. Sensenbrenner and M. Cottlerfox. Plasmaconcentrations and pharmacokinetics of dimethylsulfoxide and its metabolites in patients undergoing peripheral-blood stem-cell transplants. Journal of Clinical Oncology 16:610-615, 1998.
  19. Ette, E.I., H. Sun and T.M. Ludden. Balanced designs in longitudinal population pharmacokinetic studies. Journal of Clinical Pharmacology 38:417-423, 1998.
  20. Ette, E.I., H. Sun and T.M. Ludden. Ignorability and parameter-estimation in longitudinal pharmacokinetic studies. Journal of Clinical Pharmacology 38:221-226, 1998.
  21. Fletcher, C.V., E.P. Acosta, K. Henry, L.M. Page, C.R. Gross, S.P Kawle, R.P. Remmel, A. Erice and H.H. Balfour. Concentration-controlled Zidovudine therapy. Clinical Pharmacology 64:331-338, 1998.
  22. Forrest, A., S. Chodosh, M.A. Amantea, D.A. Collins and J.J. Schentag. Pharmacokinetics and pharmacodynamics of oral Grepafloxacin in patients with acute bacterial exacerbations of chronic bronchitis. Journal of Antimicrobial Chemotherapy 40:45-57, 1998.
  23. Garteiz, D.A., T. Madden, D.E. Beck, W.R. Huie, K.T. Mcmanus, J.L. Abbruzzese, W. Chen and R.A Newman. Quantitation of dolastatin-10 using HPLC/electrospray ionization mass-spectrometry – application in a phase-I clinical-trial. Cancer Chemotherapy and Pharmacology 41:299-306, 1998.
  24. Gonzales, C.E., A.H. Groll, N. Giri, D. Shetty, I. Almohsem, T. Sein, E. Feuerste, J. Bacher, S. Piscitelli and T.J. Walsh. Antifungal activity of the Pradimicin derivative BMS-181184 in the treatment of experimental pulmonary aspergillosis in persistently neutropenic rabbits. Antimicrobial Agents and Chemotherapy 42:2399-2404, 1998.
  25. Groll, A.H., T. Sein, V. Petraiti., R. Petraiti., B. Callende., C.E. Gonzales, N. Giri, J. Bacher, S. Piscitelli and T.J. Walsh. Compartmental pharmacokinetics and tissue drug distribution of the Pradimicin derivative BMS-188184 in rabbits. Antimicrobial Agents and Chemotherapy 42:2700-2705, 1998.
  26. Haberkorn, U., M.E. Belleman, L. Gerlach, I. Morr, H. Trojan, G. Brix, A. Altmann, J. Doll and G. Vankaick. Uncoupling of 2-fluoro-2-deoxyglucose transport of phosphorylation in rat hepatoma during gene-therapy with HSV thymidine kinase. Gene Therapy 5:880-887, 1998.
  27. Haidar, S.H., J.E. Moreton, Z.M. Liang, J.F. Hoke, K.T. Muir and N.D. Eddington ND. The pharmacokinetics and electroencephalogram response of Remifentanil alone and in combination with Esmolol in the rat. Pharmaceutical Research 14(12):1817-1823, 1998.
  28. Houghton, P.J., C.F. Stewart, J. Thompson, V.M. Santana, W.L. Furman and H.S. Friedman. Preclinical and Clinical Results with Irinotecan – Extending principles learned in model systems to clinical trials design. Oncology New York 12(8):84-93, 1998.
  29. Hurst, A.K., A. Shotan, K. Hoffman, J. Johnson, T.M. Goodwin, R. Koda and U. Elkayan. Pharmacokinetic and pharmacodynamic evaluation of Atenolol during and after pregnancy. Pharmacothe. 18:840-846, 1998.
  30. Hutson, P.R., K.D. Tutsch, R. Rago, R. Arzoomanian, D. Alberti, M. Pomplun, D. Church, R. Marnocha, A.L. Cheng, N. Kehrli and G. Wilding. Renal clearance, tissue distribution, and ca-125 responses in a phase-I trial of Suramin. Clinical Cancer Research 4:1429-1436, 1998.
  31. Jackson, K.A. and S.E. Rosenbaum. The application of population pharmacokinetics to the drug development process. Drug Development and Industrial Pharmacy 24(12):1155-1162, 1998.
  32. Jacquez, J.A. Design of experiments. Journal of the Franklin Institute-Engineering and Applied Mathamatics 335B(2):259-279, 1998.
  33. Jelliffe, R.W., A. Schumitzky, D. Bayard, M. Milman, M. Vanguilder, X. Wang, F. Jiang. X. Barbaut and P. Maire. Model-based, goal-oriented, individualized drugtherapy – linkage of population modeling new multiple model dosage design, Bayesian feedback and individualized target goals. Clinical Pharmacokinetics 34:57-77, 1998.
  34. Jodrell, D.I., A. Bowman, M. Stewart, N. Dunlop, R. French, A. Maclellan, J. Cummings and J.F. Smyth. Dose limiting neurotoxicity in a phase-I study of Penclomedine (NSC-388720, CRC-88-04), a synthetic alpha-picoline derivative, administered intravenously. British Journal of Cancer 77:808-811, 1998.
  35. Keller, F., D. Czock, D. Zellner and M. Giehl. Relationship between pharmacokinetic half-life and pharmacodynamic half-life in effect-time modeling. International Journal of Clinical Pharmacology and Therapeutics 36:168-175, 1998.
  36. Knebel, W., J.C. Davis, W.D. Sanders, B. Fessler, C. Yarboro, F. Pucino and D.T. Boumpas. The pharmacokinetics and pharmacodynamics of fludarabine in rheumatoidarthritis. Phamacotherapy 18:1224-1229, 1998.
  37. Kort, J.J. Impairment of the excitatory amino-acid-transport in astroglial cells infected with the human-immunodeficiency-virus type-1. AIDS Research and Human Retroviruses 14:1329-1339, 1998.
  38. Krzyzanski, W and W.J. Jusko. Caution in use of empirical equations for pharmacodynamic indirect response models. Journal of Pharmacokinetics and Biopharmaceutics 26(6):735-741, 1998.
  39. Lares-Asseff, I., G. Lugo-Goytia, M.G. Perez-Guille, J. Flores-Perez, H. Juarez-Olguin and M.D.R. Moreno. Bayesian pharmacokinetics of Cefuroxime in critically ill septic children. Revista De Invetigacion Clinica 50(4):311-316, 1998.
  40. Levasseur, L.M., A. Delon, W.R. Greco, P. Faury, S. Bouquet and W. Couet. Development of a new quantitative approach for the isobolographic assessment of the convulsant interaction between Pefloxacin and Theophylline in rats. Pharmaceutical Research 15:1069-1076, 1998.
  41. Levasseur, L.M., H. Faessel, H.K. Slocum and W.R. Greco. Implications for clinical pharmacodynamic studies of the statistical characterization of an in vitro antiproliferation assay. Journal of Pharmacokinetics and Biopharmaceutics 26(6):717-733, 1998.
  42. Lodi, C.A., A. Terminassian, L. Beydon and M. Ursino. Modeling cerebral autoregulation and CO2 reactivity in patients with severe head-injury. American Journal of Physiology-Heart and Circulatory Physiology 43:H1729-H1741, 1998.
  43. Lowis, S.P., L. Price, A.D.J. Pearson, D.R. Newell and M. Cole. Study of the feasibility and accuracy of pharmacokinetically guided Etopodside dosing in children. British Journal of Cancer 77:2318-2323, 1998.
  44. Lugo, S.I., Z.M. Liang and M.D. Eddington. Pharmacokinetics and pharmacodynamics of mivacurium stereoisomers in beagle dogs using twitch height and train-of-4 response. Biopharmaceutics and Drug Disposition 19:485-491, 1998.
  45. Luzier, A.B., A. Forrest, M. Abelman, F.I. Hawari, J.J. Schentag and J.L. Izzo. Impact of the angiotensin-converting enzyme-inhibitor underdosing on rehospitalization rates in congestive-heart-failure. American Journal of Cardiology 82:465-469, 1998.
  46. Martinjimenez, T. and J.E. Riviere. Population pharmacokinetics in veterinary-medicinepotential use for therapeutic drug-monitoring and prediction of tissue residues and review. Journal of Veterinary Pharmacokinetics 21:167-189, 1998.
  47. McLeod, H.L., C.M. Kearns, J.G. Kuhn and R. Bruno. Evaluation of the linearity of Docetaxel pharmacokinetics. Cancer Chemotherapy and Pharmacology 42(2):155-159, 1998.
  48. McSharry, J.M., N.S. Lurain, G.L. Drusano, A. Landay, J. Manischewitz, M. Nokta, M. Ogorman, H.M. Shapiro, A. Weinberg, P. Reichelderfer and C. Crumpacker. Flow cytometric determination of ganciclovir susceptibilities of human cytomegalovirus clinical isolates. Journal of Clinical Microbiology 36:958-964, 1998.
  49. McSharry, J.M., N.S. Lurain, G.L. Drusano, A. Landay, J. Manische, M. Nokta, M. Ogorman, H.M. Shapiro, A. Weinberg and P. Reicheld. Flow cytometric determination of ganciclovir susceptibilities of human cytomegalovirus clinical isolates. Journal of Clinical Microbiology 36:958-964, 1998.
  50. McSharry, J.M., N.S. Lurain, G.L. Drusano, A. Landay, M. Nokta, M. Ogorman, A. Weinberg, H.M. Shapiro, P.S. Reicheld and C.S. Crumpack. Rapid ganciclovir susceptibility assay using flow-cytometry for human cytomegalovirus clinical isolates. Antimicrobial Agents and Chemotherapy 42:2326-2331, 1998.
  51. Messinger, Y., Y. Yanishevski, O. Ek, T. Zeren, B. Waurzyniak, R. Gunther, L. Chelstrom, M. Chandanlanglie, E. Schneider, D.E. Myers, W. Evans and F.M. Uckun. In-vivo toxicity and pharmacokinetic features of B43 (Anti-Cd19)-genistein immunoconjugate in nonhuman-primates. Clinical Cancer Research 4:165-170, 1998.
  52. Mestorino, O.N. and J.O Errecalde. Chloramphenicol pharmacokinetics after intravenous and intramuscular administration in sheep. Journal of Veterinary Medicine Series A-Physiology Pathology Clinical Medicine 45:175-180, 1998.
  53. Oreilly, S. S.D. Baker, S. Sartorius, E.K. Rowinsky, M. Finizio, G.M. Lubiniecki, L.B. Grochow, J.E. Gray, H.J. Pieniaszek and R.C. Donehower. A phase-I and pharmacological study of Dmp-840 administered by 24-hour infusion. Annals of Oncology 9:101-104, 1998.
  54. Paradiso-Hardy, F.L., S.E. Walker and S.K. Bowles. Steady-state pharmacokinetics of Propranolol in healthy male-volunteers. International Journal of Clinical Pharmacokinetics 36:370-375, 1998.
  55. Park, K., D. Verotta, S.K. Gupta and L.B. Sheiner. Use of a pharmacokinetic /pharmacodynamic model to design an optimal dose input profile. Journal of Pharmacokinetics and Biopharmaceutics 26:471-492, 1998.
  56. Pawlik, C.A., P.J. Houghton, C.F. Stewart, P.J. Cheshire, L.B. Richmond and M.K. Banks. Effective schedules of exposure of medulloblastoma and rhabdomyosarcoma xenografts to Topotecan correlate with in-vitro assays. Clinical Cancer Research 4:1995-2002, 1998.
  57. Peloquin, C.A., A.E. Bulpitt, G.S. Jaresko, R.W. Jelliffe, G.T. James and D.E. Nix. Pharmacokinetics of Pyrazinamide under fasting conditions, with food, and with antacids. Pharmacotherapy 18(6):1205-1211, 1998.
  58. Peloquin, C.A., G.S. Jaresko, C.L. Yong, A.C.F. Keung, A.E. Bulpitt and R.W. Jelliffe. Population pharmacokinetic modeling of Isoniazid, Rifampin, and Pyrazinamide. Antimicrobial Agents and Chemotherapy 41:2670-2679, 1998.
  59. Piscitelli, S.C., A. Forrest, S. Vogel, D. Chaitt, J. Metcalf, R. Stevens, M. Baseler, R.T. Davey and J.A. Kovacs. Pharmacokinetic modeling of recombinant interleukin-2 in patients with human immunodeficiency virus infection. Clinical Pharmacology and Therapeutics 64(5):492-498, 1998.
  60. Piscitelli, S.C., W.D. Figg, B. Hahn, G. Kelly, S. Thomas, and R.E.Walker. Single-dose pharmacokinetics of Thalidomide in human immunodeficiency virus-infected patients. Antimicrobial Agents and Chemotherapy 41:2797-2799, 1998.
  61. Piscittelli, S.C., S. Vogel, W.D. Figg, S. Raje, A. Forrest, J.A. Metcalf, M. Baseler and J. Falladon. Altreation in Indinavir clearance during interleukin-2 infusions in patients infected with the human-immunodeficiency-virus. Pharmacotherapy 18:1212- 1216, 1998.
  62. Preston, S.L., G.L. Drusano, A.L. Berman, C.L. Fowler, A.T. Chow, B. Dornseif, V. Reichl, J. Natarajan, F.A Wong and M. Corrado. Levofloxacin population pharmacokinetics and creation of a demographic-model for prediction of individual-drug clearance in patients with serious community-acquired infection. Antimicrobial Agents and Chemotherapy 42:1098-1104, 1998.
  63. Preston, S.L., G.L. Drusano, A.L. Berman, C.L.Fowler, A.T. Chow, B. Dornseif, V. Reichl, J. Natarajan and M. Corrado. Pharmacodynamics of Levofloxacin – a new paradigm for early clinical-trials. Jama-Journal of the American Medical Association 279:125-129, 1998.
  64. Ramanathan, M. Analysis of intracellular Th1 cytokine secretion data using parametric methodology. Cytometry 32:147-156, 1998.
  65. Relling, M.V., Y. Yanishevski, J. Nemec, W.E. Evans, J.M. Boyett, F.G. Behm and C.H. Pui. Etoposide and Antimetabolite pharmacology in patients who develop secondary acute myeloid-leukemia. Leukemia 12:346-352, 1998.
  66. Rosner, G.L. and P. Muller. Bayesian population pharmacokinetic and pharmacodynamic analyses using mixture-models. Journal of Pharmacokinetics and Biopharmaceutics 25:209-233, 1998.
  67. Rowinsky, E.K., S.D Baker, K. Burks, S. Oreilly, R.C. Donehower and L.B. Grochow. High-dose Topotecan with granulocyte-colony-stimulating factor in fluoropyrimidinerefractory colorectal-cancer – a phase-II and pharmacodynamic study. Annals of Oncology 9:173-180, 1998.
  68. Sharma, A., P.H. Slugg, J.L. Hammett and W.J. Jusko. Clinical pharmacokinetics and pharmacodynamics of a new squalene synthase inhibitor, BMS-188494, in healthy volunteers. Journal of Clinical Pharmacology 38:1116-1121, 1998.
  69. Sharma, A., W.F. Ebling and W.J. Jusko. Precursor-dependent indirect pharmacodynamic response model for tolerance and rebound phenomena. Journal of Pharmaceutical Sciences 87(12):1577-1584, 1998.
  70. Shelton, M.J. Previous infection with helicobacter-pylori is the primary determinant of spontaneous gastric hypoacidity in human immunodeficiency virus-infected outpatients. Clin. Inf. D. 27:739-745, 1998.
  71. Shrager, R.I., G.H. Weiss and R.G.S. Spencer. Optimal time spacings for T-2 measurements- monodexponential and biexponential systems. NMR Biomedical 11:297-305, 1998.
  72. Siu, L.L., A.M. Oza, E.A. Eisenhauer, P.S. Firby, J.J. Thiessen, M. Michael, N. Wainman, J. Manzo, R. Feld, R.A. Goldberg and M.J. Moore. Phase-I and pharmacological study of 9- aminocamptothecin colloidal dispersion formulation given as a 24- hour continuous-infusion weekly times 4 every 5 weeks. Journal of Clinical Oncology 16:1122-1130, 1998.
  73. Snoeck, E., K.V. Donck, P. Jacqmin, H. Vanbelle, A.G. Dupont, A. Vanpeer and M. Danhof. Physiological red-blood-cell kinetic-model to explain the apparent discrepancy between adenosine breakdown inhibition and nucleoside transporter occupancy of Draflazine. Journal of Pharmacology and Experimental Therapeutics 286:142-149, 1998.
  74. Stewart, C.F., A.J. Gajjar, R.L Heideman and P.J. Houghton. Penetration of Topotecan into cerebrospinal fluid after intravenous injection. Onkologie 21:22-24, 1998.
  75. Sun, Y.N., D.C. DuBois, R.R. Almon and W.J. Jusko. Fourth-generation model for corticosteroid pharmacodynamics: A model for methylprednisolone effects on receptor/gene-mediated glucocorticoid receptor down-regulation and tyrosine aminotransferase induction in rat liver. Journal of Pharmacokinetics and Biopharmaceutics 26(3):289-317, 1998.
  76. Sun, Y.N., D.C. DuBois, R.R. Almon, N.A. Pyszczynski and W.J. Jusko. Dose-dependence and repeated-dose studies for receptor/gene-mediated pharmacodynamics of methylprednisolone on glucocorticoid receptor down-regulation and tyrosine aminotransferase induction in rat liver. Journal of Pharmacokinetics and Biopharmaceutics 26(6):619-648, 1998.
  77. Sun, Y.N. and W.J. Jusko. Transit compartments versus gamma-distribution function to model signal-transduction processes in pharmacodynamics. Journal of Pharmaceutical Sciences 87:732-737, 1998.
  78. Synold, T.W., E.M. Newman, M. Carroll, F.M. Muggia, S. Groshen, K. Johnson and J.N. Doroshow. Cellular but not plasma pharmacokinetics of Lometrexol correlate with the occurrence of cumulative hematological toxicity. Clinical Cancer Research 4:2349-2355, 1998.
  79. Tanikawa, K., Y. Matsumoto and M. Pukuoka. Development of a computer-program, MDGP, for population pharmacokinetic analysis written using ANSI-C language on wide platforms. Biological and Pharmaceutical Bulletin 21:847-852, 1998.
  80. Terziivanov, D., I. Atanasov and V. Dimitrov. Population pharmacokinetics of Ciprofloxacin in patients with liver impairments analyzed by NPEM2 algorithm- retrospective study. International Journal of Clinical Pharmacokinetics 36:376-382, 1998.
  81. Thomas, J.K., A. Forrest, S.M. Bhavnani, J.M. Hyatt, A. Cheng, C.H. Ballow and J.J. Schentag. Pharmacodynamic evaluation of factors associated with the development of bacterial-resistance in acutely ill patients during therapy. Antimicrobial Agents and Chemotherapy 42:521-527, 1998.
  82. Thuma, P.E., N.F. Olivieri, G.F. Mabeza, G. Biemba, D. Parry, S. Zulu, F.F. Fassos, R.A. Mcclelland, G. Koren, G.M. Brittenham and V.R. Gordeuk. Assessment of the effect of the oral iron chelator deferiprone on asymptomatic plasmodium-falciparum parasitemia in humans. American Journal of Tropical Medicine and Hygiene 58:358- 364, 1998.
  83. Uckun, F.M., R.K. Narla, T. Zeren, Y. Yanishevski, D.E. Myers, B. Waurzyniak, O. Ek, E. Schneider, Y. Messinger, L.M. Chelstrom, R. Gunther and W. Evans. In-vivo toxicity, pharmacokinetics, and anticancer activity of genistein linked to recombinant human epidermal growth-factor. Clinical Cancer Research 4:1125-1134, 1998.
  84. Venook, A.P., M.J. Egorin, G.L. Rosner, T.D. Brown, T.M. Jahan, G. Batist, R. Hohl, D. Budman, M.J. Ratain, C.M. Kearns and R.L. Schilsky. Phase-I and pharmacokinetic trial of Paclitaxel in patients with hepatic-dysfunction – cancer and leukemia group-B-9264. Journal of Clinical Oncology 16:111-1819, 1998.
  85. Vucenik, I., K. Tantivejkul, Z.S. Zhang, K.E. Cole, I. Saied and A.M. Shamsuddin. IP6 in treatment of liver cancer I. IP6 inhibits growth and reverses transformed phenotype in Hepg2 human liver cancer cell line. Anticancer Research 18(6A):4083-4090, 1998.
  86. Welles, L., M.W. Saville, J. Lietzau, J.M. Pluda, K.M. Wyvill, I. Feuerstein,W.D. Figg, R. Lush, J. Odom, W.H. Wilson, M.T. Fajardo, R.W. Humphrey, E. Feigal, D. Tuck, S.M. Steinberg, S. Broder and R. Yarchoan. Phase-II trial with dose titration of Paclitaxel for the therapy of human immunodeficiency virus-associated kaposis-sarcoma. Journal of Clinical Oncology 16:1112-1121, 1998.
  87. Williams, L.E., M.R. Lewis, G.G Bebb, K.G. Clarke, T.L. Odommaryon, J.E. Shively and A.A. Raubitschek. Biodistribution of in-111-labeled and Y-90-labeled dota and maleimidocysteineamido-dota conjugated to chimeric anticarcinoembryonic antigenantibody in xenograft-bearing nude-mice – comparison of stable and chemically labile linker systems. Bioconjugate Chemistry 9:358-361, 1998.
  88. Wolf, W., V. Waluch and C.A. Presant. Non-invasive F-19-NMRS of 5-fluorouracil in pharmacokinetics and pharmacodynamic studies. NMR In Biomedicine 11(7):380- 387, 1998.
  89. Wong, S.L. and G.R. Granneman. Modeling of sertindole pharmacokinetic disposition in healthy volunteers in short term dose-escalation studies. Journal of Pharmaceutical Sciences 87(12):1629-1631, 1998.
  90. Wu, H.L., A.A. Ding, and V. Desgrutto. Estimation of HIV dynamic parameters. Statistics in Medicine 17:2463-2485, 1998.
  91. Wu, G., F. Pea, P. Cossettini and M. Furlanut. Effect of the number of samples on Bayesian and non-linear least-squares individualization: A study of Cyclosporin treatment of hematological patients with multidrug resistance. Journal of Pharmacy and Pharmacology 50:343-349, 1998.
  92. Yu, L.X. and G.L. Amidon. Saturable small intestinal drug absorption in humans: Modeling and interpretation of Cefatrizine data. European Journal of Pharmaceutics and Biopharmaceutics 45(2):199-203, 1998.
  93. Zamboni, W.C., A.J. Gajjar, T.D. Mandrell, S.L. Einhaus, M.K. Danks, W.P. Rogers, R.L. Heideman, P.J. Houghton and C.F. Stewart. A four-hour Topotecan infusion achieves cytotoxic exposure throughout the neuraxis in the nonhuman primate model: Implications for treatment of children with metastatic medulloblastoma. Clinical Cancer Research 4(10):2537-2544, 1998.
  94. Zamboni, W.C., A.J. Gajjar, R.L. Heideman, J.H. Beijnen, H. Rosing, P.J. Houghton and C.F. Stewart. Phenytoin alters the disposition of Topotecan and N-Desmethyl Topotecan in a patient with medulloblastoma. Clinical Cancer Research 4:783-789, 1998.
  95. Zamboni, W.C., C.F. Stewart, P.J. Cheshire, L.B. Richmond, S.K. Hanna, X.L. Luo, C. Poquette, J.P. Mcgovren, J.A. Houghton and P.J. Houghton. Studies of the efficacy and pharmacology of Irinotecan against human colon-tumor xenograft models. Clinical Cancer Research 4:743-753, 1998.
  96. Zamboni, W.C., C.F. Stewart, J. Thompson, V.M. Santana, P. Cheshire, L.B. Richmond, X.L. Luo, C. Poquette, J.A. Houghton and P.J. Houghton. Relationship between Topotecan systemic exposure and tumor-response in human neuroblastoma xenografts. Journal of the National Cancer Institute 90:505-511, 1998.
  97. Zamboni W.C., P.J. Houghton, R.K. Johnson, J.L.Hulstein, W.R.Crom, PJ.Cheshire, S.K. Hanna, L.B. Richmond, X.L. Luo and C.F. Stewart. Probenecid alters Topotecan systemic and renal disposition by inhibiting renal tubular secretion. Journal of Pharmacology and Experimental Therapeutics 284:89-94, 1998.